Press coverage about Akari Therapeutics (NASDAQ:AKTX) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Akari Therapeutics earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 44.9118540842361 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of Akari Therapeutics (NASDAQ AKTX) traded down $0.23 on Thursday, hitting $2.12. 138,131 shares of the stock were exchanged, compared to its average volume of 154,326. The stock has a market capitalization of $32.34, a price-to-earnings ratio of -0.79 and a beta of -7.82. Akari Therapeutics has a 12-month low of $1.79 and a 12-month high of $22.20.
A number of equities research analysts have recently weighed in on AKTX shares. ValuEngine raised shares of Akari Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, November 30th. Zacks Investment Research lowered shares of Akari Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 16th. Finally, B. Riley started coverage on shares of Akari Therapeutics in a report on Thursday, February 8th. They set a “neutral” rating and a $3.00 price objective on the stock. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. Akari Therapeutics has an average rating of “Hold” and an average target price of $6.38.
ILLEGAL ACTIVITY NOTICE: “Akari Therapeutics (AKTX) Given Daily News Impact Score of 0.11” was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.thelincolnianonline.com/2018/03/15/akari-therapeutics-aktx-given-daily-news-impact-score-of-0-11.html.
About Akari Therapeutics
Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.